ArticleActa pharmaceutica Sinica. B2024

Discovery of first-in-class DOT1L inhibitors against the R231Q gain-of-function mutation in the catalytic domain with therapeutic potential of lung cancer.

Zehui Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.